soft.report

New polygenic risk score sharpens risk stratification for open-angle glaucoma

A study in Ophthalmology found that people in the top decile of a new polygenic score had about a 10-fold higher risk of open-angle glaucoma and, on average, were diagnosed about 25 years earlier than those in the bottom decile.

Published Source date: November 12, 2026 soft.report Team

Open-angle glaucoma (OAG) is highly heritable, and roughly half of all cases remain undiagnosed. A study published online on November 12, 2026, in Ophthalmology describes an enhanced polygenic risk score (PRS) for the disease and examines whether it is ready for clinical use.

What was done

The team, led by researchers at QIMR Berghofer and Flinders University in Australia, built the score from genome-wide association study (GWAS) data on more than 6 million people of multiple ancestries. The model combined glaucoma-related traits, including intraocular pressure, optic disc parameters, and ocular hypertension.

Performance was tested in several cohorts (Australia, the United States, UK Biobank, and non-European ancestry groups). Outcomes included OAG risk, age at diagnosis, treatment escalation, glaucoma surgery, and risk among first-degree relatives.

What they found

  • Among Australians of European ancestry, people in the top 10% of the score had roughly a 10-fold higher risk of OAG than everyone else (OR 10.04; 95% CI 7.43–13.59). The group's previous score reached an OR of 4.2.
  • In US European-ancestry data the OR was 9.09 (95% CI 5.09–16.26); in UK Biobank it was 4.91 (95% CI 4.25–5.69).
  • Performance was lower in other ancestries: OR 4.01 in South Asian, 3.39 in East Asian, and 2.26 to 3.81 in African-ancestry populations, depending on the cohort.
  • Comparing the highest with the lowest decile, risk was about 100-fold higher (OR 96.83; 95% CI 52.61–178.21), and glaucoma appeared about 25 years earlier on average.
  • The score was also associated with treatment escalation in early disease, glaucoma surgery, and OAG risk in first-degree relatives. According to the university, in a long-term cohort of glaucoma suspects and early cases, almost 1 in 4 people in the highest-risk group needed surgery by age 80, compared with none in the lowest-risk group.

Limitations

  • Performance is clearly strongest in people of European ancestry; the authors themselves say equity across ancestries needs to improve. Admixed populations, such as those in Latin America, were not the focus of validation.
  • This is an association and risk-prediction study, not a trial showing that screening with the score reduces blindness.
  • Several authors are affiliated with Seonix Bio, which offers the test through an accredited genotyping workflow, and with 23andMe.

Why it matters in practice

If confirmed in other populations, a score like this could help decide who benefits from earlier screening and closer follow-up, such as relatives of glaucoma patients, and help allocate resources more efficiently for people at low risk. It does not replace the eye exam: tonometry, optic disc assessment, OCT, and visual fields remain the basis of diagnosis.

"Genetic information could help us identify who may benefit from earlier screening," senior author Professor Jamie Craig said in a Flinders University statement.

Read the original paper in Ophthalmology.

Sources

  1. Step change in glaucoma polygenic risk score performance enables clinical utility — Ophthalmology, November 12, 2026
  2. Step change in glaucoma polygenic risk score performance enables clinical utility — PubMed, November 12, 2026
  3. New test could help identify glaucoma risk decades before vision loss — Flinders University, November 17, 2026

Informational content, written with AI assistance from the cited sources. It does not replace reading the original study or a medical evaluation.

Ophthalmology reports in your own template

The AI reads the exam, drafts the report in your template, and you review and sign. 15-day free trial, no card.

Discover soft.report

Read also